NYSE
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.4B | $7.4B | $7.5B | $7.0B | $6.8B | $6.6B |
| Gross profit | $2.1B | $2.5B | $2.6B | $2.4B | $2.3B | $2.1B |
| Operating income | $706.8M | $972.2M | $1.1B | $696.4M | $1.1B | -$246.2M |
| Net income | $116.6M | $572.6M | $686.5M | $321.1M | $711.5M | -$530.2M |
| Diluted EPS | $0.09 | $0.85 | $1.01 | $0.47 | $1.04 | -$0.78 |
| Operating cash flow | $929.8M | $953.6M | $843.6M | $870.0M | $840.8M | $623.8M |
| Free cash flow | $868.2M | $842.5M | $710.2M | $723.6M | $692.0M | $495.0M |
| Gross margin | 32.5% | 33.9% | 34.6% | 33.9% | 33.6% | 32.7% |
| Operating margin | 11.1% | 13.2% | 15.0% | 10.0% | 16.0% | -3.8% |
| Net margin | 1.8% | 7.8% | 9.1% | 4.6% | 10.5% | -8.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.7B | $1.7B | $1.6B | $1.7B | $1.6B | $1.7B | $1.6B |
| Gross profit | $581.5M | $564.4M | $562.9M | $534.9M | $554.1M | $526.5M | $523.9M | $500.7M |
| Operating income | $175.8M | $124.6M | $638.1M | $147.4M | $128.8M | -$648.8M | $126.4M | $99.5M |
| Net income | $92.9M | $57.8M | $500.4M | $64.5M | $64.7M | -$711.8M | $52.4M | $43.3M |
| Diluted EPS | $0.14 | $0.08 | $0.73 | $0.09 | $0.09 | -$1.04 | $0.08 | $0.06 |
| Operating cash flow | $281.1M | $244.8M | $173.3M | $109.3M | $154.4M | $207.4M | $152.7M | $58.7M |
| Free cash flow | $235.3M | $204.0M | $145.8M | $81.3M | $124.8M | $171.7M | $117.2M | $25.2M |
| Gross margin | 34.1% | 32.9% | 33.4% | 33.8% | 32.9% | 32.4% | 31.5% | 31.7% |
| Operating margin | 10.3% | 7.3% | 37.8% | 9.3% | 7.7% | -40.0% | 7.6% | 6.3% |
| Net margin | 5.5% | 3.4% | 29.7% | 4.1% | 3.8% | -43.8% | 3.1% | 2.7% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-21 | Walker Corey· President, VWR Dist. & Servs. | Tax withholding | 3,010 | $9.58 | $28,835.80 | filing |
| 2026-05-08 | LUCIER GREGORY T | Buy | 10,000 | $8.32 | $83,200.00 | filing |
| 2026-05-07 | Murthy Mala | Award | 25,270 | $0.00 | $0.00 | filing |
| 2026-05-07 | LUCIER GREGORY T | Award | 25,270 | $0.00 | $0.00 | filing |
| 2026-05-07 | Dingemans Simon | Award | 25,270 | $0.00 | $0.00 | filing |
| 2026-05-07 | Makin Louise | Award | 25,270 | $0.00 | $0.00 | filing |
| 2026-05-07 | Massaro Joseph R | Award | 25,270 | $0.00 | $0.00 | filing |
| 2026-05-07 | MEHRA SANJEEV K | Award | 25,270 | $0.00 | $0.00 | filing |
| 2026-05-07 | SEVERINO MICHAEL | Award | 25,270 | $0.00 | $0.00 | filing |
| 2026-05-07 | SUMME GREGORY L | Award | 25,270 | $0.00 | $0.00 | filing |
| 2026-05-01 | Dingemans Simon | Buy | 25,000 | $8.14 | $203,500.00 | filing |
| 2026-05-01 | Brellier Ludovic· EVP, Bioscience & Medtech | Award | 146,566 | $0.00 | $0.00 | filing |
| 2026-04-03 | Eck Steven W· SVP & Chief Accounting Officer | Award | 31,645 | $0.00 | $0.00 | filing |
| 2026-03-10 | MEHRA SANJEEV K | Buy | 125,000 | $8.01 | $1.0M | filing |
| 2026-02-24 | Eck Steven W· SVP & Chief Accounting Officer | Tax withholding | 452 | $9.11 | $4,117.72 | filing |
| 2026-02-24 | Hankamer Brittany· EVP, Chief HR Officer | Tax withholding | 359 | $9.11 | $3,270.49 | filing |
| 2026-02-23 | Gourdier Benoit· EVP, Bioscience & Medtech | Tax withholding | 3,029 | $8.89 | $26,927.81 | filing |
| 2026-02-23 | Jones R. Brent· EVP, Chief Financial Officer | Tax withholding | 2,805 | $8.89 | $24,936.45 | filing |
| 2026-02-23 | Sokenu Claudius· EVP, Chief Legal & Compliance | Tax withholding | 2,376 | $8.89 | $21,122.64 | filing |
| 2026-02-23 | Eck Steven W· SVP & Chief Accounting Officer | Tax withholding | 2,017 | $8.89 | $17,931.13 | filing |
| 2026-02-23 | Hankamer Brittany· EVP, Chief HR Officer | Tax withholding | 1,324 | $8.89 | $11,770.36 | filing |
| 2026-02-20 | Jones R. Brent· EVP, Chief Financial Officer | Tax withholding | 9,506 | $9.03 | $85,839.18 | filing |
| 2026-02-20 | Walker Corey· President, VWR Dist. & Servs. | Tax withholding | 4,963 | $9.03 | $44,815.89 | filing |
| 2026-02-20 | Gourdier Benoit· EVP, Bioscience & Medtech | Tax withholding | 4,160 | $9.03 | $37,564.80 | filing |
| 2026-02-20 | Sokenu Claudius· EVP, Chief Legal & Compliance | Tax withholding | 2,919 | $9.03 | $26,358.57 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.